Par Pharmaceutical Inc. began to investigate potential trade secret theft by QuVa Pharma Inc. after FDA granted QuVa's request to allow vasopressin to be used in compounding and numerous employees involved in development of Par's Vasostrict (vasopressin injection) jumped to QuVa.
Par, a subsidiary of Endo International PLC, alleges in an Aug. 14 suit against QuVa and three...





